Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients.

Leukemia - 1 Oct 2008

Meuleman N, Stamatopoulos B, Dejeneffe M, El Housni H, Lagneaux L, Bron D

Abstract excerpt

Soluble CD23 (sCD23) levels correlate with the stage, prognosis and overall survival (OS) of patients with chronic lymphocytic leukemia (CLL). Therefore, we prospectively evaluated sCD23 doubling time (sCD23DT) as a prognostic factor for time to treatment (TTT) and OS in 56 newly diagnosed and untreated CLL patients at Binet stage A, and compared it to the most commonly used biological prognostic factors:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ADP-ribosyl Cyclase 1
Share to Flow Cytometry

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunoglobulin Heavy Chains

Share to Immunoglobulin Variable Region

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Lipoprotein Lipase

Share to Receptors, IgE

Share to ZAP-70 Protein-Tyrosine Kinase

Source

Identifiers

PMID: 18633433
DOI: 10.1038/leu.2008.190

Genes

CD38
LPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients.PMID 18633433Read ↗

Defining the prognosis of early stage chronic lymphocytic leukaemia patients.Semantic proximity Read ↗

Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group.Semantic proximity Read ↗

White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia.Semantic proximity Read ↗

Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia.Semantic proximity Read ↗

Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice.Semantic proximity Read ↗

Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study.Semantic proximity Read ↗

Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.Semantic proximity Read ↗

A Molecular Score by Quantitative PCR as a New Prognostic Tool at Diagnosis for Chronic Lymphocytic Leukemia PatientsSemantic proximity Read ↗

Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?Semantic proximity Read ↗

CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia.Semantic proximity Read ↗

Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients.Semantic proximity Read ↗

CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.